title: Carboplatin and vinorelbine in advanced non-small-cell lung cancer.
abstract: A total of 32 patients with advanced non-small-cell lung cancer were treated with carboplatin (350 mg/m2, day 1) and vinorelbine (days 1 and 8) every 28 days. A response rate of 28% (95% confidence limits 12.5 - 43.7%) was observed. The activity of this combination was demonstrated in an outpatient setting with acceptable toxicity.
authors.affiliation: Oncologia Medica, Ospedale S. Andrea, Loc Felettino, La Spezia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: E
authors.initials: E
authors.lastname: Ghio
authors.forename: P L
authors.initials: PL
authors.lastname: Losardo
authors.forename: M
authors.initials: M
authors.lastname: Landucci
authors.forename: F
authors.initials: F
authors.lastname: Vaira
authors.forename: A
authors.initials: A
authors.lastname: Vigani
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D000077235:Vinorelbine